• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?

作者信息

Sadeghi Setayesh, Kargar Mona

机构信息

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Eur J Clin Pharmacol. 2021 Sep;77(9):1427-1428. doi: 10.1007/s00228-021-03118-9. Epub 2021 Mar 16.

DOI:10.1007/s00228-021-03118-9
PMID:33723657
Abstract
摘要

相似文献

1
Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?帕唑帕尼和舒尼替尼的临床相关毒性与使用弱CYP3A4和P-gp抑制剂之间是否存在关联？
Eur J Clin Pharmacol. 2021 Sep;77(9):1427-1428. doi: 10.1007/s00228-021-03118-9. Epub 2021 Mar 16.
2
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.帕唑帕尼和舒尼替尼的临床相关毒性与弱 CYP3A4 和 P-gp 抑制剂的使用之间的关联。
Eur J Clin Pharmacol. 2020 Apr;76(4):579-587. doi: 10.1007/s00228-020-02828-w. Epub 2020 Jan 13.
3
Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions and in Patient Samples.帕唑帕尼和舒尼替尼醛反应性代谢物在毒性、药物相互作用及患者样本中的作用
Chem Res Toxicol. 2020 Jan 21;33(1):181-190. doi: 10.1021/acs.chemrestox.9b00205. Epub 2019 Sep 26.
4
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.伊马替尼、舒尼替尼和帕唑帕尼：从固定剂量给药迈向药代动力学指导的个体化给药。
Br J Clin Pharmacol. 2020 Feb;86(2):258-273. doi: 10.1111/bcp.14185. Epub 2020 Jan 21.
5
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience.全面老年评估是一线舒尼替尼或帕唑帕尼治疗的转移性肾细胞癌老年患者的独立预后因素：单中心经验。
J Geriatr Oncol. 2021 Mar;12(2):290-297. doi: 10.1016/j.jgo.2020.09.009. Epub 2020 Sep 21.
6
Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.CYP3A4*22 对癌症患者帕唑帕尼药代动力学的影响。
Clin Pharmacokinet. 2019 May;58(5):651-658. doi: 10.1007/s40262-018-0719-5.
7
Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer.帕唑帕尼与舒尼替尼治疗转移性肾细胞癌期间骨骼肌面积和去脂体重的变化。
Cancer Chemother Pharmacol. 2019 Apr;83(4):735-742. doi: 10.1007/s00280-019-03779-5. Epub 2019 Jan 24.
8
Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.通过分子对接研究细胞色素P450（CYP）3A4对帕唑帕尼的代谢行为预测
Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):465-8. doi: 10.1007/s13318-015-0252-y. Epub 2015 Mar 4.
9
Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.查尔森合并症指数对一线舒尼替尼或帕唑帕尼治疗的局部晚期和转移性肾细胞癌患者剂量限制性毒性及生存的影响。
J Oncol Pharm Pract. 2020 Jul;26(5):1147-1155. doi: 10.1177/1078155219890032. Epub 2019 Dec 2.
10
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.帕唑帕尼与舒尼替尼治疗具有高风险特征的转移性肾细胞癌患者的疗效比较
Cancer Chemother Pharmacol. 2016 Aug;78(2):325-32. doi: 10.1007/s00280-016-3093-8. Epub 2016 Jun 21.

本文引用的文献

1
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.帕唑帕尼和舒尼替尼的临床相关毒性与弱 CYP3A4 和 P-gp 抑制剂的使用之间的关联。
Eur J Clin Pharmacol. 2020 Apr;76(4):579-587. doi: 10.1007/s00228-020-02828-w. Epub 2020 Jan 13.
2
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.分化型和髓样甲状腺癌患者中酪氨酸激酶抑制剂（TKI）副作用的管理。
Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):349-361. doi: 10.1016/j.beem.2017.04.012. Epub 2017 May 10.
3
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
帕唑帕尼的临床药代动力学和药效学：迈向优化剂量。
Clin Pharmacokinet. 2017 Sep;56(9):987-997. doi: 10.1007/s40262-017-0510-z.
4
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.用于个体化帕唑帕尼给药的治疗药物监测：一项药代动力学可行性研究。
Ther Drug Monit. 2015 Jun;37(3):331-8. doi: 10.1097/FTD.0000000000000141.
5
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.治疗相关性疲劳与索拉非尼、舒尼替尼和帕唑帕尼在晚期实体瘤患者中的应用：临床试验的最新综述和荟萃分析。
Int J Cancer. 2015 Jan 1;136(1):1-10. doi: 10.1002/ijc.28715. Epub 2014 Feb 7.